Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Antidepressant Drugs: MAOIs and Other Agents01:23

Antidepressant Drugs: MAOIs and Other Agents

1.2K
Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...
1.2K
Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy01:30

Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy

1.1K
Various diagnostic tests are employed in the diagnostic process for Inflammatory Bowel Disease (IBD), particularly to differentiate between Crohn's disease and ulcerative colitis.
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
1.1K
Depressive Disorders: Etiology01:27

Depressive Disorders: Etiology

874
Depressive disorders result from a complex interplay of biological, psychological, and sociocultural factors, each contributing uniquely to the development and persistence of the condition. Understanding these factors provides critical insight into the multifaceted nature of depression.
Biological Factors in Depression
Biological predispositions significantly influence the risk of developing depressive disorders. Genetic studies highlight the role of variations in the serotonin transporter...
874
Depression: Overview01:18

Depression: Overview

1.2K
Depression is a prevalent mental illness marked by persistent sadness and lack of interest in previously enjoyable activities. It can take several forms, including major depression, persistent depressive disorder, and bipolar I and II disorders. Symptoms range from emotional changes like chronic worry to physical changes like sleep disturbances and suicidal thoughts. From a neurobiological perspective, depression is believed to be triggered by abnormalities in the brain's prefrontal cortex,...
1.2K
Antidepressant Drugs: Overview01:25

Antidepressant Drugs: Overview

2.1K
Antidepressant drugs are a class of medications primarily used for treating various mood disorders, including major depression, anxiety disorders, and other related conditions. These medicines work by modulating the neurotransmitter balance within the brain, alleviating depressive symptoms. Antidepressants can be broadly categorized into several groups according to their mechanism of action and chemical structure: Selective Serotonin Reuptake Inhibitors (SSRIs), Serotonin-Norepinephrine...
2.1K
Antidepressant Drugs: Tricyclics, SSRIs, and SNRIs01:28

Antidepressant Drugs: Tricyclics, SSRIs, and SNRIs

2.2K
Tricyclic Antidepressants (TCAs), including Desipramine (Norpramin), Imipramine (Tofranil), Clomipramine (Anafranil), and Amitriptyline (Elavil), inhibit serotonin and norepinephrine reuptake and also block other receptors. They are used for depression, pain conditions, and insomnia. Common adverse effects include anticholinergic effects, sedation, orthostatic hypotension, and weight gain. They have a narrow therapeutic window and so require plasma-level monitoring. Abrupt discontinuation can...
2.2K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Pharmacological treatment of anhedonic depression: the role of dopaminergic and anti-inflammatory mechanisms.

Expert opinion on pharmacotherapy·2026
Same author

Building Care in the Heart of the Moment - Exploring the Process of Collaboration for the Making of Flexible Assertive Community Treatment.

International journal of integrated care·2026
Same author

Inhibition of kynurenine 3-monooxygenase (KMO) reduces fentanyl and sucrose intake and relapse-like behaviour in rats.

British journal of pharmacology·2026
Same author

Efficacy and target engagement of dopamine agonist pramipexole for anhedonic depression: a randomized placebo-controlled trial.

Nature medicine·2026
Same author

Generalizability of findings from neurobiological studies of individuals with first-episode psychosis: a cohort study.

Schizophrenia (Heidelberg, Germany)·2026
Same author

The role of proinflammatory response and the kynurenine pathway in the association between childhood maltreatment and lifetime substance use disorder.

Neurobiology of stress·2026

Related Experiment Video

Updated: Apr 14, 2026

A High-performance Liquid Chromatography Measurement of Kynurenine and Kynurenic Acid: Relating Biochemistry to Cognition and Sleep in Rats
07:04

A High-performance Liquid Chromatography Measurement of Kynurenine and Kynurenic Acid: Relating Biochemistry to Cognition and Sleep in Rats

Published on: August 19, 2018

11.1K

Kynurenine pathway metabolites are increased in inflammatory depression and decrease with omega-3 treatment.

Jesper Lindahl1,2, Gustav Söderberg Veibäck1,3, Klara Suneson1,4

  • 1Unit for Biological and Precision Psychiatry, Department of Clinical Sciences Lund, Lund University, Lund, Sweden.

Brain, Behavior, & Immunity - Health
|April 13, 2026
PubMed
Summary

Inflammatory depression is linked to elevated kynurenine pathway (KP) metabolites. Omega-3 fatty acids reduced these metabolites and improved depression, suggesting KP biomarkers may predict treatment response.

Keywords:
Kynurenine pathwayMajor depressive disorderN-3 PUFAsNutraceuticalsProbioticsTryptophan

More Related Videos

Simultaneous Quantification of Selected Kynurenines Analyzed by Liquid Chromatography-Mass Spectrometry in Medium Collected from Cancer Cell Cultures
10:38

Simultaneous Quantification of Selected Kynurenines Analyzed by Liquid Chromatography-Mass Spectrometry in Medium Collected from Cancer Cell Cultures

Published on: May 9, 2020

3.9K
Network Pharmacology and Validation of the Antidepressant Mechanisms of Qiangzhifang in a Chronic Restraint Stress-induced Depression Rat Model
08:15

Network Pharmacology and Validation of the Antidepressant Mechanisms of Qiangzhifang in a Chronic Restraint Stress-induced Depression Rat Model

Published on: June 6, 2025

741

Related Experiment Videos

Last Updated: Apr 14, 2026

A High-performance Liquid Chromatography Measurement of Kynurenine and Kynurenic Acid: Relating Biochemistry to Cognition and Sleep in Rats
07:04

A High-performance Liquid Chromatography Measurement of Kynurenine and Kynurenic Acid: Relating Biochemistry to Cognition and Sleep in Rats

Published on: August 19, 2018

11.1K
Simultaneous Quantification of Selected Kynurenines Analyzed by Liquid Chromatography-Mass Spectrometry in Medium Collected from Cancer Cell Cultures
10:38

Simultaneous Quantification of Selected Kynurenines Analyzed by Liquid Chromatography-Mass Spectrometry in Medium Collected from Cancer Cell Cultures

Published on: May 9, 2020

3.9K
Network Pharmacology and Validation of the Antidepressant Mechanisms of Qiangzhifang in a Chronic Restraint Stress-induced Depression Rat Model
08:15

Network Pharmacology and Validation of the Antidepressant Mechanisms of Qiangzhifang in a Chronic Restraint Stress-induced Depression Rat Model

Published on: June 6, 2025

741

Area of Science:

  • Neuroscience
  • Biochemistry
  • Psychiatry

Background:

  • The kynurenine pathway (KP) is implicated in inflammatory depression due to neuroactive metabolite accumulation.
  • Understanding KP metabolite differences in inflammatory versus non-inflammatory depression is crucial.

Purpose of the Study:

  • Investigate KP metabolites in major depressive disorder (MDD) with inflammation compared to non-inflammatory MDD and healthy controls.
  • Assess changes in KP metabolites with omega-3 polyunsaturated fatty acids (n-3 PUFAs) and probiotic interventions.
  • Determine if KP metabolite levels and changes correlate with clinical antidepressant response.

Main Methods:

  • Combined data from two antidepressant clinical trials involving n-3 PUFAs and *Limosilactobacillus reuteri* probiotic.
  • Stratified 170 MDD patients into inflammatory (hs-CRP ≥1 mg/L) and non-inflammatory (hs-CRP <1 mg/L) groups, including 80 healthy controls.
  • Analyzed baseline KP metabolite levels (quinolinic acid, 3-hydroxykynurenine, kynurenine), treatment-associated changes, and their relationship to clinical outcomes.

Main Results:

  • Inflammatory depression group showed significantly higher baseline levels of quinolinic acid (QUIN), 3-hydroxykynurenine (3-HK), and kynurenine compared to non-inflammatory depression and healthy controls.
  • N-3 PUFAs significantly decreased QUIN and 3-HK levels, while probiotics and placebo did not.
  • Higher baseline KP metabolite levels and greater decreases with n-3 PUFAs were associated with better clinical response.

Conclusions:

  • Evidence suggests KP activation in MDD, specifically within an inflammatory subgroup.
  • These findings highlight the potential role of KP biomarkers in predicting antidepressant response to n-3 PUFAs in patients with low-grade inflammation.
  • Further research is warranted to explore KP activation biomarkers for predicting antidepressant efficacy.